Israel Englander Intra Cellular Therapies, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 889,102 shares of ITCI stock, worth $81.2 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

889,102

Previous 282,744 214.45%

Holding current value

$81.2 Million

Previous $19.6 Million 211.24%

% of portfolio

0.03%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $39.3 Million - $48.4 Million	606,358 Added 214.45%	889,102 $60.9 Million
Q1 2024 May 15, 2024	SELL	$64.37 - $75.65 $5.84 Million - $6.87 Million	-90,761 Reduced 24.3%	282,744 $19.6 Million
Q4 2023 Feb 14, 2024	SELL	$46.37 - $73.65 $12 Million - $19.1 Million	-259,409 Reduced 40.99%	373,505 $26.8 Million
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $7.35 Million - $8.94 Million	134,526 Added 26.99%	632,914 $40.1 Million
Q1 2023 May 15, 2023	SELL	$43.8 - $56.99 $39.3 Million - $51.2 Million	-898,232 Reduced 64.31%	498,388 $27 Million
Q4 2022 Feb 14, 2023	SELL	$44.07 - $54.45 $19.6 Million - $24.2 Million	-444,429 Reduced 24.14%	1,396,620 $73.9 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $34.3 Million - $48.2 Million	803,772 Added 77.49%	1,841,049 $85.7 Million
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $13.4 Million - $20.5 Million	311,808 Added 42.98%	1,037,277 $59.2 Million
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $3.58 Million - $5.73 Million	92,312 Added 14.58%	725,469 $44.4 Million
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $3.66 Million - $5.56 Million	-103,994 Reduced 14.11%	633,157 $33.1 Million
Q3 2021 Nov 15, 2021	BUY	$28.72 - $42.49 $2.7 Million - $4 Million	94,173 Added 14.65%	737,151 $27.5 Million
Q2 2021 Aug 16, 2021	SELL	$29.3 - $44.5 $4.54 Million - $6.9 Million	-155,074 Reduced 19.43%	642,978 $26.2 Million
Q1 2021 May 17, 2021	SELL	$30.8 - $39.51 $24.5 Million - $31.5 Million	-796,101 Reduced 49.94%	798,052 $27.1 Million
Q4 2020 Feb 16, 2021	SELL	$23.34 - $32.22 $9.38 Million - $12.9 Million	-401,743 Reduced 20.13%	1,594,153 $50.7 Million
Q3 2020 Nov 16, 2020	BUY	$17.61 - $31.86 $31.8 Million - $57.6 Million	1,808,241 Added 963.6%	1,995,896 $51.2 Million
Q2 2020 Aug 14, 2020	SELL	$14.35 - $26.64 $3.85 Million - $7.15 Million	-268,478 Reduced 58.86%	187,655 $4.82 Million
Q1 2020 May 14, 2020	BUY	$12.31 - $33.12 $2.42 Million - $6.5 Million	196,279 Added 75.53%	456,133 $7.01 Million
Q4 2019 Feb 14, 2020	SELL	$7.26 - $38.49 $7.09 Million - $37.6 Million	-977,114 Reduced 78.99%	259,854 $8.92 Million
Q3 2019 Nov 14, 2019	BUY	$7.47 - $14.03 $8.23 Million - $15.5 Million	1,101,616 Added 813.89%	1,236,968 $9.24 Million
Q2 2019 Aug 14, 2019	SELL	$10.65 - $14.29 $6.15 Million - $8.25 Million	-577,306 Reduced 81.01%	135,352 $1.76 Million
Q1 2019 May 14, 2019	SELL	$10.9 - $14.09 $2.32 Million - $3 Million	-212,847 Reduced 23.0%	712,658 $8.68 Million
Q4 2018 Feb 14, 2019	BUY	$10.36 - $20.96 $3.95 Million - $8 Million	381,508 Added 70.13%	925,505 $10.5 Million
Q3 2018 Nov 14, 2018	SELL	$17.77 - $22.9 $7.22 Million - $9.31 Million	-406,508 Reduced 42.77%	543,997 $11.8 Million
Q2 2018 Aug 14, 2018	BUY	$17.33 - $23.4 $6.53 Million - $8.81 Million	376,537 Added 65.6%	950,505 $16.8 Million
Q1 2018 May 15, 2018	SELL	$15.16 - $25.49 $13.4 Million - $22.5 Million	-880,976 Reduced 60.55%	573,968 $12.1 Million
Q4 2017 Feb 14, 2018	BUY	$14.27 - $16.79 $1.03 Million - $1.21 Million	71,980 Added 5.2%	1,454,944 $21.1 Million
Q3 2017 Nov 14, 2017	BUY	$10.77 - $22.1 $14.9 Million - $30.6 Million	1,382,964	1,382,964 $21.8 Million

Others Institutions Holding ITCI

# of Institutions

402

Shares Held

89.5M

Call Options Held

301K

Put Options Held

277K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.62B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account